1.

National Asthma Council Australia. Asthma Management Handbook 2006. Melbourne: National Asthma Council Australia, 2006.

2.

Henderson J, Knox S, Pan Y, Britt H. Changes in asthma management in Australian general practice. Prim Care Respir J 2004; 13: 138-43.

3.

Robertson CF, Price D, Henry R et al. Short-course montelukast for intermittent asthma in children: a randomized controlled trial. Am J Respir Crit Care Med 2007; 175: 323-9.

4.

Fitzgerald DA, Mellis CM. Leukotriene receptor antagonists in virus-induced wheezing: evidence to date. Treat Respir Med 2006; 5: 407-17.

5.

Volovitz B, Duenas-Meza E, Chmielewska-Szewczyk DA et al. Comparison of oral montelukast and inhaled cromolyn with respect to preference, satisfaction, and adherence: a multi-center, randomized, open-label, crossover study in children with mild to moderate persistent asthma. Curr Ther Res Clin Exp 2000; 61: 490-506.

6.

Vuillermin P, South M, Robertson C. Parent-initiated oral corticosteroid therapy for intermittent wheezing illnesses in children. Cochrane Database Syst Rev 2006; 3.

7.

Oommen A, Lambert PC, Grigg J. Effi cacy of a short course of parent-initiated oral prednisolone for viral wheeze in children aged 1-5 years: randomised controlled trial. Lancet 2003; 362: 1433-8.

8.

McKean M, Ducharme F. Inhaled steroids for episodic viral wheeze of childhood. Cochrane Database Syst Rev 2000; 1.

9.

Merck Sharp & Dohme (MSD). Singulair (Montelukast sodium) Australian Approved Product Information. Melbourne: MSD, 2007.

10.

Pajaron-Fernandez M, Garcia-Rubia S, Sanchez-Solis M, Garcia- Marcos L. Montelukast administered in the morning or evening to prevent exercise-induced bronchoconstriction in children. Pediatr Pulmonol 2006; 41: 222-7.

11.

Peroni DG, Piacentini GL, Ress M et al. Time efficacy of a single dose of montelukast on exercise-induced asthma in children. Pediatr Allergy Immunol 2002; 13: 434-7.

12.

de Benedictis FM, del Giudice MM, Forenza N et al. Lack of tolerance to the protective effect of montelukast in exercise-induced bronchoconstriction in children. Eur Respir J 2006; 28: 291-5.

13.

Knorr B, Franchi LM, Bisgaard H et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics 2001; 108: E48.

14.

Knorr B, Matz J, Bernstein JA et al. Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group. JAMA 1998; 279: 1181-6.

15.

Becker AB, Kuznetsova O, Vermeulen J et al. Linear growth in prepubertal asthmatic children treated with montelukast, beclomethasone, or placebo: a 56-week randomized double-blind study. Pediatric Montelukast Linear Growth Study Group. Ann Allergy Asthma Immunol 2006; 96: 800-7.

16.

Garcia Garcia ML, Wahn U, Gilles L et al. Montelukast, compared with fl uticasone, for control of asthma among 6- to 14-year-old patients with mild asthma: The MOSAIC Study. Pediatrics 2005; 116: 360-9.

17.

Becker A, Swern A, Tozzi CA et al. Montelukast in asthmatic patients 6 years-14 years old with an FEV1 > 75%. Curr Med Res Opin 2004; 20: 1651-9.

18.

Meyer KA, Arduino JM, Santanello NC et al. Response to montelukast among subgroups of children aged 2 to 14 years with asthma. J Allergy Clin Immunol 2003; 111: 757-62.

19.

Luskin AT, Bernstein A. ‘Real-world' effectiveness of daily controller medicine in children with mild persistent asthma. Ann Allergy Asthma Immunol 2003; 90: 543-9.

20.

Sorkness CA, Lemanske RF, Mauger DT et al. Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: The Pediatric Asthma Controller Trial. J Allergy Clin Immunol 2007; 119: 64-72.

21.

Zeiger RS, Szefl er SJ, Phillips BR et al. Response profi les to fl uticasone and montelukast in mild-to-moderate persistent childhood asthma. J Allergy Clin Immunol 2006; 117: 45-52.

22.

Ostrom NK, Decotiis BA, Lincourt WR et al. Comparative effi cacy and safety of low-dose fl uticasone propionate and montelukast in children with persistent asthma. J Pediatr 2005; 147: 213-20.

23.

Jat GC, Mathew JL, Singh M. Treatment with 400 microg of inhaled budesonide vs 200 microg of inhaled budesonide and oral montelukast in children with moderate persistent asthma: randomized controlled trial. Ann Allergy Asthma Immunol 2006; 97: 397-401.

24.

Szefl er SJ, Phillips BR, Martinez FD et al. Characterization of withinsubject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol 2005; 115: 233-42.

25.

Bisgaard H, Zielen S, Garcia-Garcia LM et al. Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma. Am J Respir Crit Care Med 2005; 171: 315-22.

26..

Anderson SD. How does exercise cause asthma attacks? Curr Opin Allergy Clin Immunol 2006; 6: 37-42.

27.

Hallstrand TS, Moody MW, Aitken ML et al. Airway immunopathology of asthma with exercise-induced bronchoconstriction. J Allergy Clin Immunol 2005; 116: 586-93.

28.

Anderson SD. Single-dose agents in the prevention of exerciseinduced asthma: a descriptive review. Treat Respir Med 2004; 3: 365-79.

29.

Philip G, Villaran C, Pearlman DS et al. Protection against exercise-induced bronchoconstriction two hours after a single oral dose of montelukast. J Asthma 2007; 44: 213-17.

30.

Melo RE, Sole D, Naspitz CK. Exercise-induced bronchoconstriction in children: montelukast attenuates the immediate-phase and latephase responses. J Allergy Clin Immunol 2003; 111: 301-7.

31.

Kemp JP, Dockhorn RJ, Shapiro GG et al. Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma. J Pediatr 1998; 133: 424-8.

32

Kim JH, Lee SY, Kim HB et al. Prolonged effect of montelukast in asthmatic children with exercise-induced bronchoconstriction. Pediatr Pulmonol 2005; 39: 162-6.

33

Anderson SD, Caillaud C, Brannan JD. Beta2-agonists and exercise-induced asthma. Clin Rev Allergy Immunol 2006; 31: 163-80.

34

Wilson AM, O'Byrne PM, Parameswaran K. Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis. Am J Med 2004; 116: 338-44.

35.

Michele TM, Lu S, Malice M-P et al. Combination of montelukast and loratadine in seasonal allergic rhinitis: An analysis of three spring studies. J Allergy Clin Immunol 2000; 104: S387 [Abstract].

36.

Michele TM et al. Combination of montelukast and loratadine improves quality of life in seasonal allergic rhinitis: An analysis of three spring studies. Allergy 2000; 55 (Suppl 63): 42 [Abstract].

37.

Razi C, Bakirtas A, Harmanci K, Turktas I, Erbas D. Effect of montelukast on symptoms and exhaled nitric oxide levels in 7- to 14-year-old children with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2006; 97: 767-74.

38.

Chen ST, Lu KH, Sun HL et al. Randomized placebo-controlled trial comparing montelukast and cetirizine for treating perennial allergic rhinitis in children aged 2-6 years. Pediatr Allergy Immunol 2006;17: 49-54.

39.

Chang AB, Winter D, Acworth JP. Leukotriene receptor antagonist for prolonged non-specifi c cough in children. Cochrane Database Syst Rev 2006; 2.

40.

van Adelsberg J, Moy J, Wei LX et al. Safety, tolerability, and exploratory effi cacy of montelukast in 6- to 24-month-old patients with asthma. Curr Med Res Opin 2005; 21: 971-9.

41.

Straub DA, Moeller A, Minocchieri S et al. The effect of montelukast on lung function and exhaled nitric oxide in infants with early childhood asthma. European Respir J 2005; 25: 289-94.

42.

Phipatanakul W, Nowak-Wegrzyn A, Eggleston PA et al. The effi cacy of montelukast in the treatment of cat allergen-induced asthma in children. J Allergy Clin Immunol 2002; 109: 794-9.

43.

Phipatanakul W, Greene C, Downes SJ et al. Montelukast improves asthma control in asthmatic children maintained on inhaled corticosteroids. Ann Allergy Asthma Immunol 2003; 91: 49-54.

44.

Peroni D, Bodini A, Miraglia Del Giudice M et al. Effect of budesonide and montelukast in asthmatic children exposed to relevant allergens. Allergy 2005; 60: 206-10.

45.

Bisgaard H; Study Group on Montelukast and Respiratory Syncytial Virus. A randomized trial of montelukast in respiratory syncytial viruspostbronchiolitis. Am J Respir Crit Care Med 2003; 167: 379-83.